Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclona...(tumor which could allow for thegrowth an...),Health

Date:8/7/2008

tumor which could allow for the growth and survival of tumors involved in several types of cancers, including CLL, multiple myeloma, non-Hodgkins lymphoma, melanoma, ovarian cancer and neuroblastoma. Laboratory data have shown that ALXN6000 blocks binding of CD200 to the CD200 receptor, which has been shown to enhance the immune response to tumors and reduce tumor growth. The anti-tumor activity of ALXN6000 was reported in the January 2008 issue of the Journal of Immunology. (1)

About CLL

CLL is the second most common type of leukemia in adults. (2) The American Cancer Society estimates that, in 2008, there will be approximately 15,000 new cases of CLL in the United States. Approximately 4,000 people in this country are expected to die of CLL during 2008. (3) CLL, which involves production of abnormal lymphocytes (white blood cells) starts in the bone marrow and can spread through the blood to the lymph nodes, spleen, liver and other parts of the body. (3) B-cell CLL is characterized by clonal expansion of abnormal B lymphocytes. Patients with CLL also may develop enlargement of the spleen and lymph nodes, and pancytopenia (depletion of red and white blood cells and platelets), ultimately resulting in hemorrhage, infection and death. (4)

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for Alexion's first product, Soliris(R) (eculizumab), for all patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease. In June 2007, the European Commission granted market
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
2. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
3. GeoVax Secures $10 Million Financing Commitment
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
6. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
7. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
8. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
11. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System